nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A7—Estradiol—osteoporosis	0.0931	0.151	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0931	0.151	CbGbCtD
Ethosuximide—CYP3A5—Estradiol—osteoporosis	0.0698	0.113	CbGbCtD
Ethosuximide—CYP3A4—Estropipate—osteoporosis	0.0656	0.106	CbGbCtD
Ethosuximide—CYP3A4—Calcitriol—osteoporosis	0.0656	0.106	CbGbCtD
Ethosuximide—CYP3A4—Ergocalciferol—osteoporosis	0.0524	0.0849	CbGbCtD
Ethosuximide—CYP3A4—Raloxifene—osteoporosis	0.0438	0.0708	CbGbCtD
Ethosuximide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0423	0.0684	CbGbCtD
Ethosuximide—CYP3A4—Cholecalciferol—osteoporosis	0.0338	0.0547	CbGbCtD
Ethosuximide—CYP3A4—Conjugated Estrogens—osteoporosis	0.031	0.0502	CbGbCtD
Ethosuximide—CYP3A4—Estradiol—osteoporosis	0.0272	0.0441	CbGbCtD
Ethosuximide—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00138	0.046	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00129	0.0432	CbGpPWpGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00128	0.0426	CbGpPWpGaD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00105	0.035	CbGpPWpGaD
Ethosuximide—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00101	0.00286	CcSEcCtD
Ethosuximide—Irritability—Estradiol—osteoporosis	0.001	0.00285	CcSEcCtD
Ethosuximide—Haematuria—Zoledronate—osteoporosis	0.001	0.00285	CcSEcCtD
Ethosuximide—Immune system disorder—Risedronate—osteoporosis	0.000982	0.00279	CcSEcCtD
Ethosuximide—Agranulocytosis—Zoledronate—osteoporosis	0.000982	0.00279	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000981	0.00278	CcSEcCtD
Ethosuximide—Mediastinal disorder—Risedronate—osteoporosis	0.00098	0.00278	CcSEcCtD
Ethosuximide—Mental disorder—Ethinyl Estradiol—osteoporosis	0.000977	0.00277	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000971	0.00276	CcSEcCtD
Ethosuximide—Malnutrition—Ethinyl Estradiol—osteoporosis	0.000971	0.00276	CcSEcCtD
Ethosuximide—Eye disorder—Pamidronate—osteoporosis	0.000966	0.00274	CcSEcCtD
Ethosuximide—Abdominal pain upper—Estradiol—osteoporosis	0.000961	0.00273	CcSEcCtD
Ethosuximide—Nervous system disorder—Estropipate—osteoporosis	0.000959	0.00272	CcSEcCtD
Ethosuximide—Mental disorder—Risedronate—osteoporosis	0.000953	0.0027	CcSEcCtD
Ethosuximide—Breast disorder—Estradiol—osteoporosis	0.000951	0.0027	CcSEcCtD
Ethosuximide—Skin disorder—Estropipate—osteoporosis	0.00095	0.0027	CcSEcCtD
Ethosuximide—Cramp muscle—Estradiol—osteoporosis	0.000947	0.00269	CcSEcCtD
Ethosuximide—Malnutrition—Risedronate—osteoporosis	0.000947	0.00269	CcSEcCtD
Ethosuximide—Immune system disorder—Pamidronate—osteoporosis	0.000934	0.00265	CcSEcCtD
Ethosuximide—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.000934	0.00265	CcSEcCtD
Ethosuximide—Urinary tract disorder—Zoledronate—osteoporosis	0.000933	0.00265	CcSEcCtD
Ethosuximide—Mediastinal disorder—Pamidronate—osteoporosis	0.000932	0.00264	CcSEcCtD
Ethosuximide—Nervous system disorder—Raloxifene—osteoporosis	0.000929	0.00264	CcSEcCtD
Ethosuximide—Connective tissue disorder—Zoledronate—osteoporosis	0.000928	0.00263	CcSEcCtD
Ethosuximide—Urethral disorder—Zoledronate—osteoporosis	0.000926	0.00263	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Etidronic acid—osteoporosis	0.000924	0.00262	CcSEcCtD
Ethosuximide—Skin disorder—Raloxifene—osteoporosis	0.00092	0.00261	CcSEcCtD
Ethosuximide—Nervous system disorder—Ibandronate—osteoporosis	0.000919	0.00261	CcSEcCtD
Ethosuximide—Skin disorder—Ibandronate—osteoporosis	0.000911	0.00258	CcSEcCtD
Ethosuximide—Muscle spasms—Risedronate—osteoporosis	0.00091	0.00258	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—DKK1—osteoporosis	0.000908	0.0303	CbGpPWpGaD
Ethosuximide—Nausea—Ergocalciferol—osteoporosis	0.000903	0.00256	CcSEcCtD
Ethosuximide—Malnutrition—Pamidronate—osteoporosis	0.0009	0.00255	CcSEcCtD
Ethosuximide—Urticaria—Etidronic acid—osteoporosis	0.000898	0.00255	CcSEcCtD
Ethosuximide—Abdominal pain—Etidronic acid—osteoporosis	0.000893	0.00254	CcSEcCtD
Ethosuximide—Skin disorder—Calcitriol—osteoporosis	0.000892	0.00253	CcSEcCtD
Ethosuximide—Eye disorder—Zoledronate—osteoporosis	0.000883	0.0025	CcSEcCtD
Ethosuximide—Anorexia—Calcitriol—osteoporosis	0.000875	0.00248	CcSEcCtD
Ethosuximide—Abdominal discomfort—Estradiol—osteoporosis	0.000872	0.00247	CcSEcCtD
Ethosuximide—Somnolence—Estropipate—osteoporosis	0.000869	0.00247	CcSEcCtD
Ethosuximide—Muscle spasms—Pamidronate—osteoporosis	0.000865	0.00246	CcSEcCtD
Ethosuximide—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.00086	0.00244	CcSEcCtD
Ethosuximide—Immune system disorder—Zoledronate—osteoporosis	0.000853	0.00242	CcSEcCtD
Ethosuximide—Mediastinal disorder—Zoledronate—osteoporosis	0.000851	0.00242	CcSEcCtD
Ethosuximide—Eye disorder—Conjugated Estrogens—osteoporosis	0.00085	0.00241	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Estropipate—osteoporosis	0.000844	0.0024	CcSEcCtD
Ethosuximide—Fatigue—Estropipate—osteoporosis	0.000843	0.00239	CcSEcCtD
Ethosuximide—Hypersensitivity—Etidronic acid—osteoporosis	0.000833	0.00236	CcSEcCtD
Ethosuximide—Mental disorder—Zoledronate—osteoporosis	0.000827	0.00235	CcSEcCtD
Ethosuximide—Agitation—Pamidronate—osteoporosis	0.000827	0.00235	CcSEcCtD
Ethosuximide—Weight decreased—Estradiol—osteoporosis	0.000823	0.00233	CcSEcCtD
Ethosuximide—Malnutrition—Zoledronate—osteoporosis	0.000822	0.00233	CcSEcCtD
Ethosuximide—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000821	0.00233	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000821	0.00233	CcSEcCtD
Ethosuximide—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00082	0.00233	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000818	0.00232	CcSEcCtD
Ethosuximide—Somnolence—Calcitriol—osteoporosis	0.000816	0.00232	CcSEcCtD
Ethosuximide—Decreased appetite—Ibandronate—osteoporosis	0.000815	0.00231	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000809	0.0023	CcSEcCtD
Ethosuximide—Fatigue—Ibandronate—osteoporosis	0.000808	0.00229	CcSEcCtD
Ethosuximide—Leukopenia—Pamidronate—osteoporosis	0.000806	0.00229	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.0008	0.00227	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Estropipate—osteoporosis	0.0008	0.00227	CcSEcCtD
Ethosuximide—Decreased appetite—Calcitriol—osteoporosis	0.000798	0.00226	CcSEcCtD
Ethosuximide—Mental disorder—Conjugated Estrogens—osteoporosis	0.000797	0.00226	CcSEcCtD
Ethosuximide—Malnutrition—Conjugated Estrogens—osteoporosis	0.000792	0.00225	CcSEcCtD
Ethosuximide—Muscle spasms—Zoledronate—osteoporosis	0.00079	0.00224	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Alendronate—osteoporosis	0.000787	0.00223	CcSEcCtD
Ethosuximide—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000777	0.00221	CcSEcCtD
Ethosuximide—Urticaria—Estropipate—osteoporosis	0.000777	0.0022	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Raloxifene—osteoporosis	0.000774	0.0022	CcSEcCtD
Ethosuximide—Diarrhoea—Etidronic acid—osteoporosis	0.000773	0.00219	CcSEcCtD
Ethosuximide—Haematuria—Estradiol—osteoporosis	0.000773	0.00219	CcSEcCtD
Ethosuximide—Abdominal pain—Estropipate—osteoporosis	0.000773	0.00219	CcSEcCtD
Ethosuximide—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00077	0.00218	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Ibandronate—osteoporosis	0.000767	0.00218	CcSEcCtD
Ethosuximide—Urticaria—Alendronate—osteoporosis	0.000765	0.00217	CcSEcCtD
Ethosuximide—Abdominal pain—Alendronate—osteoporosis	0.000761	0.00216	CcSEcCtD
Ethosuximide—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000761	0.00216	CcSEcCtD
Ethosuximide—Nervous system disorder—Risedronate—osteoporosis	0.000758	0.00215	CcSEcCtD
Ethosuximide—Agitation—Zoledronate—osteoporosis	0.000755	0.00214	CcSEcCtD
Ethosuximide—Skin disorder—Risedronate—osteoporosis	0.000751	0.00213	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Calcitriol—osteoporosis	0.000751	0.00213	CcSEcCtD
Ethosuximide—Abdominal pain—Raloxifene—osteoporosis	0.000749	0.00212	CcSEcCtD
Ethosuximide—Urticaria—Ibandronate—osteoporosis	0.000745	0.00211	CcSEcCtD
Ethosuximide—Abdominal pain—Ibandronate—osteoporosis	0.000741	0.0021	CcSEcCtD
Ethosuximide—Leukopenia—Zoledronate—osteoporosis	0.000736	0.00209	CcSEcCtD
Ethosuximide—Urticaria—Calcitriol—osteoporosis	0.000729	0.00207	CcSEcCtD
Ethosuximide—Abdominal pain—Calcitriol—osteoporosis	0.000726	0.00206	CcSEcCtD
Ethosuximide—Hypersensitivity—Estropipate—osteoporosis	0.00072	0.00204	CcSEcCtD
Ethosuximide—Nervous system disorder—Pamidronate—osteoporosis	0.00072	0.00204	CcSEcCtD
Ethosuximide—Urinary tract disorder—Estradiol—osteoporosis	0.000719	0.00204	CcSEcCtD
Ethosuximide—Vomiting—Etidronic acid—osteoporosis	0.000719	0.00204	CcSEcCtD
Ethosuximide—Connective tissue disorder—Estradiol—osteoporosis	0.000715	0.00203	CcSEcCtD
Ethosuximide—Urethral disorder—Estradiol—osteoporosis	0.000713	0.00202	CcSEcCtD
Ethosuximide—Rash—Etidronic acid—osteoporosis	0.000713	0.00202	CcSEcCtD
Ethosuximide—Dermatitis—Etidronic acid—osteoporosis	0.000712	0.00202	CcSEcCtD
Ethosuximide—Hypersensitivity—Alendronate—osteoporosis	0.00071	0.00201	CcSEcCtD
Ethosuximide—Headache—Etidronic acid—osteoporosis	0.000708	0.00201	CcSEcCtD
Ethosuximide—Asthenia—Estropipate—osteoporosis	0.000702	0.00199	CcSEcCtD
Ethosuximide—Anorexia—Pamidronate—osteoporosis	0.0007	0.00199	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000695	0.00197	CcSEcCtD
Ethosuximide—Asthenia—Alendronate—osteoporosis	0.000691	0.00196	CcSEcCtD
Ethosuximide—Hypersensitivity—Ibandronate—osteoporosis	0.000691	0.00196	CcSEcCtD
Ethosuximide—Erythema multiforme—Estradiol—osteoporosis	0.000688	0.00195	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000684	0.00194	CcSEcCtD
Ethosuximide—Fatigue—Ethinyl Estradiol—osteoporosis	0.000683	0.00194	CcSEcCtD
Ethosuximide—Eye disorder—Estradiol—osteoporosis	0.00068	0.00193	CcSEcCtD
Ethosuximide—CYP2E1—Folate-Alcohol and Cancer Pathway—MTHFR—osteoporosis	0.00068	0.0227	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.00068	0.0227	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Calcitriol—osteoporosis	0.000676	0.00192	CcSEcCtD
Ethosuximide—Asthenia—Ibandronate—osteoporosis	0.000673	0.00191	CcSEcCtD
Ethosuximide—Nausea—Etidronic acid—osteoporosis	0.000671	0.00191	CcSEcCtD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000671	0.0224	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000669	0.0019	CcSEcCtD
Ethosuximide—Diarrhoea—Estropipate—osteoporosis	0.000669	0.0019	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000667	0.00189	CcSEcCtD
Ethosuximide—Fatigue—Risedronate—osteoporosis	0.000666	0.00189	CcSEcCtD
Ethosuximide—Diarrhoea—Alendronate—osteoporosis	0.000659	0.00187	CcSEcCtD
Ethosuximide—Asthenia—Calcitriol—osteoporosis	0.000659	0.00187	CcSEcCtD
Ethosuximide—Nervous system disorder—Zoledronate—osteoporosis	0.000658	0.00187	CcSEcCtD
Ethosuximide—Immune system disorder—Estradiol—osteoporosis	0.000657	0.00187	CcSEcCtD
Ethosuximide—Mediastinal disorder—Estradiol—osteoporosis	0.000656	0.00186	CcSEcCtD
Ethosuximide—Somnolence—Pamidronate—osteoporosis	0.000653	0.00185	CcSEcCtD
Ethosuximide—Skin disorder—Zoledronate—osteoporosis	0.000652	0.00185	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000648	0.00184	CcSEcCtD
Ethosuximide—Diarrhoea—Raloxifene—osteoporosis	0.000648	0.00184	CcSEcCtD
Ethosuximide—Dizziness—Estropipate—osteoporosis	0.000647	0.00184	CcSEcCtD
Ethosuximide—Diarrhoea—Ibandronate—osteoporosis	0.000642	0.00182	CcSEcCtD
Ethosuximide—Anorexia—Zoledronate—osteoporosis	0.00064	0.00182	CcSEcCtD
Ethosuximide—Decreased appetite—Pamidronate—osteoporosis	0.000639	0.00181	CcSEcCtD
Ethosuximide—Mental disorder—Estradiol—osteoporosis	0.000638	0.00181	CcSEcCtD
Ethosuximide—Dizziness—Alendronate—osteoporosis	0.000637	0.00181	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000634	0.0018	CcSEcCtD
Ethosuximide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000634	0.0018	CcSEcCtD
Ethosuximide—Malnutrition—Estradiol—osteoporosis	0.000634	0.0018	CcSEcCtD
Ethosuximide—Fatigue—Pamidronate—osteoporosis	0.000633	0.0018	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Risedronate—osteoporosis	0.000632	0.00179	CcSEcCtD
Ethosuximide—Urticaria—Ethinyl Estradiol—osteoporosis	0.00063	0.00179	CcSEcCtD
Ethosuximide—Diarrhoea—Calcitriol—osteoporosis	0.000628	0.00178	CcSEcCtD
Ethosuximide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000628	0.00178	CcSEcCtD
Ethosuximide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000627	0.00178	CcSEcCtD
Ethosuximide—Dizziness—Raloxifene—osteoporosis	0.000626	0.00178	CcSEcCtD
Ethosuximide—Vomiting—Estropipate—osteoporosis	0.000622	0.00176	CcSEcCtD
Ethosuximide—Dizziness—Ibandronate—osteoporosis	0.00062	0.00176	CcSEcCtD
Ethosuximide—Rash—Estropipate—osteoporosis	0.000616	0.00175	CcSEcCtD
Ethosuximide—Dermatitis—Estropipate—osteoporosis	0.000616	0.00175	CcSEcCtD
Ethosuximide—Anorexia—Conjugated Estrogens—osteoporosis	0.000616	0.00175	CcSEcCtD
Ethosuximide—Urticaria—Risedronate—osteoporosis	0.000614	0.00174	CcSEcCtD
Ethosuximide—Headache—Estropipate—osteoporosis	0.000613	0.00174	CcSEcCtD
Ethosuximide—Vomiting—Alendronate—osteoporosis	0.000612	0.00174	CcSEcCtD
Ethosuximide—Abdominal pain—Risedronate—osteoporosis	0.000611	0.00173	CcSEcCtD
Ethosuximide—Muscle spasms—Estradiol—osteoporosis	0.000609	0.00173	CcSEcCtD
Ethosuximide—Rash—Alendronate—osteoporosis	0.000607	0.00172	CcSEcCtD
Ethosuximide—Dermatitis—Alendronate—osteoporosis	0.000607	0.00172	CcSEcCtD
Ethosuximide—Headache—Alendronate—osteoporosis	0.000603	0.00171	CcSEcCtD
Ethosuximide—Vomiting—Raloxifene—osteoporosis	0.000602	0.00171	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000601	0.0017	CcSEcCtD
Ethosuximide—Rash—Raloxifene—osteoporosis	0.000597	0.00169	CcSEcCtD
Ethosuximide—Dermatitis—Raloxifene—osteoporosis	0.000597	0.00169	CcSEcCtD
Ethosuximide—Somnolence—Zoledronate—osteoporosis	0.000596	0.00169	CcSEcCtD
Ethosuximide—Vomiting—Ibandronate—osteoporosis	0.000596	0.00169	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—CAP1—osteoporosis	0.000593	0.0198	CbGpPWpGaD
Ethosuximide—Headache—Raloxifene—osteoporosis	0.000593	0.00168	CcSEcCtD
Ethosuximide—Rash—Ibandronate—osteoporosis	0.000591	0.00168	CcSEcCtD
Ethosuximide—Dermatitis—Ibandronate—osteoporosis	0.000591	0.00168	CcSEcCtD
Ethosuximide—Headache—Ibandronate—osteoporosis	0.000587	0.00167	CcSEcCtD
Ethosuximide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000584	0.00166	CcSEcCtD
Ethosuximide—Vomiting—Calcitriol—osteoporosis	0.000584	0.00166	CcSEcCtD
Ethosuximide—Decreased appetite—Zoledronate—osteoporosis	0.000583	0.00166	CcSEcCtD
Ethosuximide—Agitation—Estradiol—osteoporosis	0.000582	0.00165	CcSEcCtD
Ethosuximide—Nausea—Estropipate—osteoporosis	0.000581	0.00165	CcSEcCtD
Ethosuximide—Abdominal pain—Pamidronate—osteoporosis	0.000581	0.00165	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000579	0.00164	CcSEcCtD
Ethosuximide—Rash—Calcitriol—osteoporosis	0.000579	0.00164	CcSEcCtD
Ethosuximide—Fatigue—Zoledronate—osteoporosis	0.000578	0.00164	CcSEcCtD
Ethosuximide—Dermatitis—Calcitriol—osteoporosis	0.000578	0.00164	CcSEcCtD
Ethosuximide—Headache—Calcitriol—osteoporosis	0.000575	0.00163	CcSEcCtD
Ethosuximide—Somnolence—Conjugated Estrogens—osteoporosis	0.000574	0.00163	CcSEcCtD
Ethosuximide—Nausea—Alendronate—osteoporosis	0.000572	0.00162	CcSEcCtD
Ethosuximide—Hypersensitivity—Risedronate—osteoporosis	0.000569	0.00162	CcSEcCtD
Ethosuximide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000569	0.00161	CcSEcCtD
Ethosuximide—Nausea—Raloxifene—osteoporosis	0.000563	0.0016	CcSEcCtD
Ethosuximide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000562	0.00159	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000558	0.00158	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—CYP27A1—osteoporosis	0.000557	0.0186	CbGpPWpGaD
Ethosuximide—Fatigue—Conjugated Estrogens—osteoporosis	0.000557	0.00158	CcSEcCtD
Ethosuximide—Nausea—Ibandronate—osteoporosis	0.000557	0.00158	CcSEcCtD
Ethosuximide—Asthenia—Risedronate—osteoporosis	0.000554	0.00157	CcSEcCtD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000551	0.0184	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP27A1—osteoporosis	0.00055	0.0183	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000549	0.00156	CcSEcCtD
Ethosuximide—Nausea—Calcitriol—osteoporosis	0.000545	0.00155	CcSEcCtD
Ethosuximide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000542	0.00154	CcSEcCtD
Ethosuximide—Hypersensitivity—Pamidronate—osteoporosis	0.000541	0.00154	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000536	0.00152	CcSEcCtD
Ethosuximide—Urticaria—Zoledronate—osteoporosis	0.000533	0.00151	CcSEcCtD
Ethosuximide—Abdominal pain—Zoledronate—osteoporosis	0.00053	0.00151	CcSEcCtD
Ethosuximide—Diarrhoea—Risedronate—osteoporosis	0.000529	0.0015	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000528	0.0015	CcSEcCtD
Ethosuximide—Asthenia—Pamidronate—osteoporosis	0.000527	0.0015	CcSEcCtD
Ethosuximide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000524	0.00149	CcSEcCtD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000521	0.0174	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000515	0.0172	CbGpPWpGaD
Ethosuximide—Urticaria—Conjugated Estrogens—osteoporosis	0.000513	0.00146	CcSEcCtD
Ethosuximide—Dizziness—Risedronate—osteoporosis	0.000511	0.00145	CcSEcCtD
Ethosuximide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000511	0.00145	CcSEcCtD
Ethosuximide—Nervous system disorder—Estradiol—osteoporosis	0.000507	0.00144	CcSEcCtD
Ethosuximide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000504	0.00143	CcSEcCtD
Ethosuximide—Diarrhoea—Pamidronate—osteoporosis	0.000503	0.00143	CcSEcCtD
Ethosuximide—Skin disorder—Estradiol—osteoporosis	0.000502	0.00143	CcSEcCtD
Ethosuximide—Rash—Ethinyl Estradiol—osteoporosis	0.0005	0.00142	CcSEcCtD
Ethosuximide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000499	0.00142	CcSEcCtD
Ethosuximide—Headache—Ethinyl Estradiol—osteoporosis	0.000496	0.00141	CcSEcCtD
Ethosuximide—Hypersensitivity—Zoledronate—osteoporosis	0.000494	0.0014	CcSEcCtD
Ethosuximide—Vomiting—Risedronate—osteoporosis	0.000491	0.00139	CcSEcCtD
Ethosuximide—Rash—Risedronate—osteoporosis	0.000487	0.00138	CcSEcCtD
Ethosuximide—Dermatitis—Risedronate—osteoporosis	0.000487	0.00138	CcSEcCtD
Ethosuximide—Dizziness—Pamidronate—osteoporosis	0.000486	0.00138	CcSEcCtD
Ethosuximide—Headache—Risedronate—osteoporosis	0.000484	0.00137	CcSEcCtD
Ethosuximide—Asthenia—Zoledronate—osteoporosis	0.000481	0.00137	CcSEcCtD
Ethosuximide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000476	0.00135	CcSEcCtD
Ethosuximide—Nausea—Ethinyl Estradiol—osteoporosis	0.000471	0.00134	CcSEcCtD
Ethosuximide—Vomiting—Pamidronate—osteoporosis	0.000467	0.00133	CcSEcCtD
Ethosuximide—Asthenia—Conjugated Estrogens—osteoporosis	0.000464	0.00132	CcSEcCtD
Ethosuximide—Rash—Pamidronate—osteoporosis	0.000463	0.00131	CcSEcCtD
Ethosuximide—Dermatitis—Pamidronate—osteoporosis	0.000463	0.00131	CcSEcCtD
Ethosuximide—Headache—Pamidronate—osteoporosis	0.00046	0.00131	CcSEcCtD
Ethosuximide—Somnolence—Estradiol—osteoporosis	0.00046	0.0013	CcSEcCtD
Ethosuximide—Diarrhoea—Zoledronate—osteoporosis	0.000459	0.0013	CcSEcCtD
Ethosuximide—Nausea—Risedronate—osteoporosis	0.000459	0.0013	CcSEcCtD
Ethosuximide—Decreased appetite—Estradiol—osteoporosis	0.000449	0.00128	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000446	0.00127	CcSEcCtD
Ethosuximide—Fatigue—Estradiol—osteoporosis	0.000446	0.00127	CcSEcCtD
Ethosuximide—Dizziness—Zoledronate—osteoporosis	0.000444	0.00126	CcSEcCtD
Ethosuximide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000442	0.00125	CcSEcCtD
Ethosuximide—Nausea—Pamidronate—osteoporosis	0.000436	0.00124	CcSEcCtD
Ethosuximide—Dizziness—Conjugated Estrogens—osteoporosis	0.000427	0.00121	CcSEcCtD
Ethosuximide—Vomiting—Zoledronate—osteoporosis	0.000427	0.00121	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CAP1—osteoporosis	0.000423	0.0141	CbGpPWpGaD
Ethosuximide—Rash—Zoledronate—osteoporosis	0.000423	0.0012	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Estradiol—osteoporosis	0.000423	0.0012	CcSEcCtD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000423	0.0141	CbGpPWpGaD
Ethosuximide—Dermatitis—Zoledronate—osteoporosis	0.000423	0.0012	CcSEcCtD
Ethosuximide—Headache—Zoledronate—osteoporosis	0.00042	0.00119	CcSEcCtD
Ethosuximide—Vomiting—Conjugated Estrogens—osteoporosis	0.000411	0.00117	CcSEcCtD
Ethosuximide—Urticaria—Estradiol—osteoporosis	0.000411	0.00117	CcSEcCtD
Ethosuximide—Abdominal pain—Estradiol—osteoporosis	0.000409	0.00116	CcSEcCtD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000409	0.0136	CbGpPWpGaD
Ethosuximide—Rash—Conjugated Estrogens—osteoporosis	0.000407	0.00116	CcSEcCtD
Ethosuximide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000407	0.00116	CcSEcCtD
Ethosuximide—Headache—Conjugated Estrogens—osteoporosis	0.000405	0.00115	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6R—osteoporosis	0.000405	0.0135	CbGpPWpGaD
Ethosuximide—Nausea—Zoledronate—osteoporosis	0.000399	0.00113	CcSEcCtD
Ethosuximide—Nausea—Conjugated Estrogens—osteoporosis	0.000384	0.00109	CcSEcCtD
Ethosuximide—Hypersensitivity—Estradiol—osteoporosis	0.000381	0.00108	CcSEcCtD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000378	0.0126	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000377	0.0126	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000373	0.0124	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000372	0.0124	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—TLN1—osteoporosis	0.000372	0.0124	CbGpPWpGaD
Ethosuximide—Asthenia—Estradiol—osteoporosis	0.000371	0.00105	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—ACTG1—osteoporosis	0.000367	0.0122	CbGpPWpGaD
Ethosuximide—Diarrhoea—Estradiol—osteoporosis	0.000354	0.001	CcSEcCtD
Ethosuximide—Dizziness—Estradiol—osteoporosis	0.000342	0.00097	CcSEcCtD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000331	0.011	CbGpPWpGaD
Ethosuximide—Vomiting—Estradiol—osteoporosis	0.000329	0.000933	CcSEcCtD
Ethosuximide—Rash—Estradiol—osteoporosis	0.000326	0.000925	CcSEcCtD
Ethosuximide—Dermatitis—Estradiol—osteoporosis	0.000326	0.000924	CcSEcCtD
Ethosuximide—Headache—Estradiol—osteoporosis	0.000324	0.000919	CcSEcCtD
Ethosuximide—Nausea—Estradiol—osteoporosis	0.000307	0.000872	CcSEcCtD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000306	0.0102	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000306	0.0102	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—CYP19A1—osteoporosis	0.000293	0.00976	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP19A1—osteoporosis	0.000289	0.00963	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000274	0.00913	CbGpPWpGaD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000273	0.00911	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00027	0.00901	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TLN1—osteoporosis	0.000265	0.00884	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—ACTG1—osteoporosis	0.000262	0.00872	CbGpPWpGaD
Ethosuximide—CYP2E1—Tryptophan metabolism—CYP19A1—osteoporosis	0.000245	0.00818	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—CYP27A1—osteoporosis	0.000225	0.00749	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000222	0.0074	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP27A1—osteoporosis	0.000221	0.00738	CbGpPWpGaD
Ethosuximide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000221	0.00736	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—osteoporosis	0.000211	0.00702	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—WNT1—osteoporosis	0.000204	0.0068	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000198	0.00661	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000198	0.0066	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000196	0.00653	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000195	0.00651	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—osteoporosis	0.00018	0.00601	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—POMC—osteoporosis	0.000176	0.00587	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000175	0.00584	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000173	0.00577	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PKM—osteoporosis	0.000166	0.00553	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—FDPS—osteoporosis	0.000166	0.00553	CbGpPWpGaD
Ethosuximide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000165	0.0055	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000165	0.00549	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP27A1—osteoporosis	0.000163	0.00542	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP27A1—osteoporosis	0.000162	0.00541	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000161	0.00536	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000161	0.00535	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP27A1—osteoporosis	0.00016	0.00535	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP27A1—osteoporosis	0.00016	0.00534	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PGLS—osteoporosis	0.000157	0.00525	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GPD2—osteoporosis	0.000157	0.00525	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ATIC—osteoporosis	0.000144	0.0048	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PNP—osteoporosis	0.000144	0.0048	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000142	0.00474	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000133	0.00445	CbGpPWpGaD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000127	0.00423	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CA2—osteoporosis	0.000122	0.00408	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—OXCT1—osteoporosis	0.000122	0.00408	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—MGLL—osteoporosis	0.000119	0.00398	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000119	0.00398	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000119	0.00397	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—CYP19A1—osteoporosis	0.000118	0.00393	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP19A1—osteoporosis	0.000116	0.00388	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—IL6R—osteoporosis	0.000116	0.00387	CbGpPWpGaD
Ethosuximide—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000114	0.0038	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—IDH2—osteoporosis	0.000101	0.00338	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—LEP—osteoporosis	9.88e-05	0.0033	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.67e-05	0.00322	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.65e-05	0.00322	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP27A1—osteoporosis	9.53e-05	0.00318	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ACP5—osteoporosis	9.27e-05	0.00309	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	9.2e-05	0.00307	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	9.08e-05	0.00303	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—TPI1—osteoporosis	8.62e-05	0.00287	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP19A1—osteoporosis	8.54e-05	0.00285	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP19A1—osteoporosis	8.53e-05	0.00284	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP19A1—osteoporosis	8.43e-05	0.00281	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP19A1—osteoporosis	8.41e-05	0.0028	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—IL6R—osteoporosis	8.28e-05	0.00276	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—P4HB—osteoporosis	8.11e-05	0.0027	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GAPDH—osteoporosis	7.96e-05	0.00265	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—RAP1A—osteoporosis	7.75e-05	0.00258	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	7.55e-05	0.00252	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.46e-05	0.00249	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	7.44e-05	0.00248	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—POMC—osteoporosis	7.09e-05	0.00236	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PKM—osteoporosis	6.69e-05	0.00223	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—FDPS—osteoporosis	6.69e-05	0.00223	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PGLS—osteoporosis	6.34e-05	0.00211	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GPD2—osteoporosis	6.34e-05	0.00211	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ENO1—osteoporosis	6.26e-05	0.00209	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PSMA5—osteoporosis	6.17e-05	0.00206	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PSMA2—osteoporosis	6.17e-05	0.00206	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ATIC—osteoporosis	5.8e-05	0.00193	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PNP—osteoporosis	5.8e-05	0.00193	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.53e-05	0.00184	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—IL6—osteoporosis	5.17e-05	0.00172	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—POMC—osteoporosis	5.13e-05	0.00171	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—POMC—osteoporosis	5.12e-05	0.00171	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP19A1—osteoporosis	5.01e-05	0.00167	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—OXCT1—osteoporosis	4.93e-05	0.00164	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CA2—osteoporosis	4.93e-05	0.00164	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TGFB1—osteoporosis	4.9e-05	0.00163	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PKM—osteoporosis	4.84e-05	0.00161	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—FDPS—osteoporosis	4.84e-05	0.00161	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PKM—osteoporosis	4.83e-05	0.00161	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—FDPS—osteoporosis	4.83e-05	0.00161	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—MGLL—osteoporosis	4.8e-05	0.0016	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PGLS—osteoporosis	4.59e-05	0.00153	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GPD2—osteoporosis	4.59e-05	0.00153	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PGLS—osteoporosis	4.58e-05	0.00153	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GPD2—osteoporosis	4.58e-05	0.00153	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TNF—osteoporosis	4.57e-05	0.00152	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.48e-05	0.0015	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ATIC—osteoporosis	4.2e-05	0.0014	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PNP—osteoporosis	4.2e-05	0.0014	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PNP—osteoporosis	4.19e-05	0.0014	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ATIC—osteoporosis	4.19e-05	0.0014	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ADCY5—osteoporosis	4.09e-05	0.00136	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—IDH2—osteoporosis	4.08e-05	0.00136	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GPX1—osteoporosis	4.08e-05	0.00136	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.96e-05	0.00132	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.91e-05	0.0013	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP27A1—osteoporosis	3.84e-05	0.00128	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—MTHFR—osteoporosis	3.76e-05	0.00125	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ACP5—osteoporosis	3.74e-05	0.00125	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—IL6—osteoporosis	3.69e-05	0.00123	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—OXCT1—osteoporosis	3.57e-05	0.00119	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CA2—osteoporosis	3.57e-05	0.00119	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CA2—osteoporosis	3.56e-05	0.00119	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—OXCT1—osteoporosis	3.56e-05	0.00119	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—MGLL—osteoporosis	3.48e-05	0.00116	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—TPI1—osteoporosis	3.47e-05	0.00116	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—MGLL—osteoporosis	3.47e-05	0.00116	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—P4HB—osteoporosis	3.26e-05	0.00109	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GAPDH—osteoporosis	3.2e-05	0.00107	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—RAP1A—osteoporosis	3.12e-05	0.00104	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—POMC—osteoporosis	3.01e-05	0.001	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—IDH2—osteoporosis	2.96e-05	0.000986	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—IDH2—osteoporosis	2.95e-05	0.000984	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP27A1—osteoporosis	2.78e-05	0.000927	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP27A1—osteoporosis	2.78e-05	0.000925	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ACP5—osteoporosis	2.71e-05	0.000902	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ACP5—osteoporosis	2.7e-05	0.0009	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ENO1—osteoporosis	2.52e-05	0.000841	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—TPI1—osteoporosis	2.52e-05	0.000839	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—TPI1—osteoporosis	2.51e-05	0.000837	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PSMA5—osteoporosis	2.49e-05	0.000829	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PSMA2—osteoporosis	2.49e-05	0.000829	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—POMC—osteoporosis	2.38e-05	0.000794	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—P4HB—osteoporosis	2.36e-05	0.000789	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—P4HB—osteoporosis	2.36e-05	0.000787	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GAPDH—osteoporosis	2.32e-05	0.000774	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GAPDH—osteoporosis	2.32e-05	0.000772	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—RAP1A—osteoporosis	2.26e-05	0.000754	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—RAP1A—osteoporosis	2.26e-05	0.000752	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—FDPS—osteoporosis	2.25e-05	0.000749	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PKM—osteoporosis	2.25e-05	0.000749	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PGLS—osteoporosis	2.13e-05	0.00071	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GPD2—osteoporosis	2.13e-05	0.00071	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP19A1—osteoporosis	2.02e-05	0.000673	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ATIC—osteoporosis	1.95e-05	0.000649	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PNP—osteoporosis	1.95e-05	0.000649	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ENO1—osteoporosis	1.83e-05	0.000609	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ENO1—osteoporosis	1.82e-05	0.000608	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PSMA2—osteoporosis	1.8e-05	0.0006	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PSMA5—osteoporosis	1.8e-05	0.0006	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PSMA2—osteoporosis	1.8e-05	0.000599	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PSMA5—osteoporosis	1.8e-05	0.000599	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CA2—osteoporosis	1.66e-05	0.000552	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—OXCT1—osteoporosis	1.66e-05	0.000552	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ADCY5—osteoporosis	1.65e-05	0.000549	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GPX1—osteoporosis	1.64e-05	0.000548	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—MGLL—osteoporosis	1.61e-05	0.000538	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—MTHFR—osteoporosis	1.52e-05	0.000505	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP19A1—osteoporosis	1.46e-05	0.000487	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.46e-05	0.000486	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—IDH2—osteoporosis	1.37e-05	0.000458	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.29e-05	0.00043	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ACP5—osteoporosis	1.26e-05	0.000419	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—POMC—osteoporosis	1.21e-05	0.000404	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ADCY5—osteoporosis	1.19e-05	0.000398	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ADCY5—osteoporosis	1.19e-05	0.000397	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GPX1—osteoporosis	1.19e-05	0.000397	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GPX1—osteoporosis	1.19e-05	0.000396	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—TPI1—osteoporosis	1.17e-05	0.000389	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—MTHFR—osteoporosis	1.1e-05	0.000366	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—P4HB—osteoporosis	1.1e-05	0.000366	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—MTHFR—osteoporosis	1.1e-05	0.000365	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GAPDH—osteoporosis	1.08e-05	0.000359	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—RAP1A—osteoporosis	1.05e-05	0.00035	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—POMC—osteoporosis	8.78e-06	0.000293	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—POMC—osteoporosis	8.76e-06	0.000292	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ENO1—osteoporosis	8.48e-06	0.000283	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PSMA2—osteoporosis	8.36e-06	0.000279	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PSMA5—osteoporosis	8.36e-06	0.000279	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP19A1—osteoporosis	6.78e-06	0.000226	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ADCY5—osteoporosis	5.54e-06	0.000185	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GPX1—osteoporosis	5.52e-06	0.000184	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—MTHFR—osteoporosis	5.09e-06	0.00017	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—POMC—osteoporosis	4.07e-06	0.000136	CbGpPWpGaD
